Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Growth (Status and Outlook) 2026-2032
The global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market size is predicted to grow from US$ 221 million in 2025 to US$ 414 million in 2032; it is expected to grow at a CAGR of 9.9% from 2026 to 2032.
CD73- and DDR1-targeted drugs for digestive system tumors are therapeutic or diagnostic agents designed to selectively bind to or inhibit CD73 or discoidin domain receptor 1 (DDR1), two proteins involved in tumor growth, immune evasion, stromal remodeling, invasion and treatment resistance in gastrointestinal cancers.
CD73-targeted drugs act against ecto-5?-nucleotidase, an enzyme that converts extracellular AMP into immunosuppressive adenosine. By blocking CD73 or using CD73 as a tumor-associated imaging target, these agents aim to reduce adenosine-mediated immune suppression, improve antitumor immune responses and identify CD73-expressing lesions.
DDR1-targeted drugs act against a collagen-activated receptor tyrosine kinase that regulates tumor–stroma interactions, extracellular-matrix signaling, cancer-cell migration and fibrotic barriers. Inhibiting or targeting DDR1 may reduce tumor invasion, improve immune-cell penetration and enhance drug delivery.
United States market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key CD73 and DDR1-Targeted Drugs for Digestive System Tumors players cover Arcus Biosciences / Gilead Sciences, AstraZeneca, Akeso, TJ Bio, I-Mab Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LPI (LP Information)' newest research report, the “CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industry Forecast” looks at past sales and reviews total world CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales in 2025, providing a comprehensive analysis by region and market sector of projected CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales for 2026 through 2032. With CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD73 and DDR1-Targeted Drugs for Digestive System Tumors industry.
This Insight Report provides a comprehensive analysis of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CD73 and DDR1-Targeted Drugs for Digestive System Tumors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD73 and DDR1-Targeted Drugs for Digestive System Tumors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors.
This report presents a comprehensive overview, market shares, and growth opportunities of CD73 and DDR1-Targeted Drugs for Digestive System Tumors market by product type, application, key players and key regions and countries.
Market Segmentation
CD73- and DDR1-targeted drugs for digestive system tumors are therapeutic or diagnostic agents designed to selectively bind to or inhibit CD73 or discoidin domain receptor 1 (DDR1), two proteins involved in tumor growth, immune evasion, stromal remodeling, invasion and treatment resistance in gastrointestinal cancers.
CD73-targeted drugs act against ecto-5?-nucleotidase, an enzyme that converts extracellular AMP into immunosuppressive adenosine. By blocking CD73 or using CD73 as a tumor-associated imaging target, these agents aim to reduce adenosine-mediated immune suppression, improve antitumor immune responses and identify CD73-expressing lesions.
DDR1-targeted drugs act against a collagen-activated receptor tyrosine kinase that regulates tumor–stroma interactions, extracellular-matrix signaling, cancer-cell migration and fibrotic barriers. Inhibiting or targeting DDR1 may reduce tumor invasion, improve immune-cell penetration and enhance drug delivery.
United States market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key CD73 and DDR1-Targeted Drugs for Digestive System Tumors players cover Arcus Biosciences / Gilead Sciences, AstraZeneca, Akeso, TJ Bio, I-Mab Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LPI (LP Information)' newest research report, the “CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industry Forecast” looks at past sales and reviews total world CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales in 2025, providing a comprehensive analysis by region and market sector of projected CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales for 2026 through 2032. With CD73 and DDR1-Targeted Drugs for Digestive System Tumors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD73 and DDR1-Targeted Drugs for Digestive System Tumors industry.
This Insight Report provides a comprehensive analysis of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CD73 and DDR1-Targeted Drugs for Digestive System Tumors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD73 and DDR1-Targeted Drugs for Digestive System Tumors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors.
This report presents a comprehensive overview, market shares, and growth opportunities of CD73 and DDR1-Targeted Drugs for Digestive System Tumors market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- CD73 Target
- DDR1 Target
Segmentation by Nucleoside:
- 68Ga
- 18F
- Lu177
Segmentation by Indications:
- Gastric Cancer
- Colorectal Cancer
- Pancreatic Cancer
Segmentation by Application:
- Diagnosis
- Therapeutics
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Arcus Biosciences / Gilead Sciences
- AstraZeneca
- Akeso
- TJ Bio
- I-Mab Biopharma
- Innate Pharma
- Phanes Therapeutics
- Incyte Corp
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size (2021-2032)
2.1.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for CD73 and DDR1-Targeted Drugs for Digestive System Tumors by Country/Region (2021, 2025 & 2032)
2.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Type
2.2.1 CD73 Target
2.2.2 DDR1 Target
2.2.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type
2.2.3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
2.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Nucleoside
2.3.1 68Ga
2.3.2 18F
2.3.3 Lu177
2.3.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside
2.3.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Nucleoside (2021 VS 2025 VS 2032)
2.3.4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2021-2026)
2.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Indications
2.4.1 Gastric Cancer
2.4.2 Colorectal Cancer
2.4.3 Pancreatic Cancer
2.4.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications
2.4.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Indications (2021 VS 2025 VS 2032)
2.4.4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2021-2026)
2.5 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Application
2.5.1 Diagnosis
2.5.2 Therapeutics
2.5.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application
2.5.3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
3 CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS MARKET SIZE BY PLAYER
3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Player
3.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026)
3.1.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player (2021-2026)
3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS BY REGION
4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026)
4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Annual Revenue by Country/Region (2021-2026)
4.3 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.4 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.5 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.6 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026)
5.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
5.3 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026)
6.2 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
6.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026)
7.2 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
7.3 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors by Region (2021-2026)
8.2 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
8.3 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS MARKET FORECAST
10.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.1.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.4 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.5 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Country (2027-2032)
10.2.1 United States Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.2 Canada Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.3 Mexico Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.4 Brazil Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.3.1 China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Forecast
10.3.2 Japan Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.3 Korea Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.4 Southeast Asia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.5 India Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.6 Australia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Country (2027-2032)
10.4.1 Germany Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.2 France Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.3 UK Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.4 Italy Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.5 Russia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.5.1 Egypt Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.2 South Africa Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.3 Israel Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.4 Turkey Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.6 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Type (2027-2032)
10.7 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
11 KEY PLAYERS ANALYSIS
11.1 Arcus Biosciences / Gilead Sciences
11.1.1 Arcus Biosciences / Gilead Sciences Company Information
11.1.2 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.1.3 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Arcus Biosciences / Gilead Sciences Main Business Overview
11.1.5 Arcus Biosciences / Gilead Sciences Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.2.3 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Akeso
11.3.1 Akeso Company Information
11.3.2 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.3.3 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Akeso Main Business Overview
11.3.5 Akeso Latest Developments
11.4 TJ Bio
11.4.1 TJ Bio Company Information
11.4.2 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.4.3 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 TJ Bio Main Business Overview
11.4.5 TJ Bio Latest Developments
11.5 I-Mab Biopharma
11.5.1 I-Mab Biopharma Company Information
11.5.2 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.5.3 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 I-Mab Biopharma Main Business Overview
11.5.5 I-Mab Biopharma Latest Developments
11.6 Innate Pharma
11.6.1 Innate Pharma Company Information
11.6.2 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.6.3 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Innate Pharma Main Business Overview
11.6.5 Innate Pharma Latest Developments
11.7 Phanes Therapeutics
11.7.1 Phanes Therapeutics Company Information
11.7.2 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.7.3 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Phanes Therapeutics Main Business Overview
11.7.5 Phanes Therapeutics Latest Developments
11.8 Incyte Corp
11.8.1 Incyte Corp Company Information
11.8.2 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.8.3 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Incyte Corp Main Business Overview
11.8.5 Incyte Corp Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size (2021-2032)
2.1.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for CD73 and DDR1-Targeted Drugs for Digestive System Tumors by Country/Region (2021, 2025 & 2032)
2.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Type
2.2.1 CD73 Target
2.2.2 DDR1 Target
2.2.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type
2.2.3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
2.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Nucleoside
2.3.1 68Ga
2.3.2 18F
2.3.3 Lu177
2.3.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside
2.3.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Nucleoside (2021 VS 2025 VS 2032)
2.3.4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2021-2026)
2.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Indications
2.4.1 Gastric Cancer
2.4.2 Colorectal Cancer
2.4.3 Pancreatic Cancer
2.4.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications
2.4.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Indications (2021 VS 2025 VS 2032)
2.4.4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2021-2026)
2.5 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Segment by Application
2.5.1 Diagnosis
2.5.2 Therapeutics
2.5.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application
2.5.3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
3 CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS MARKET SIZE BY PLAYER
3.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Player
3.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026)
3.1.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player (2021-2026)
3.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS BY REGION
4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026)
4.2 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Annual Revenue by Country/Region (2021-2026)
4.3 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.4 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.5 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
4.6 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026)
5.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
5.3 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026)
6.2 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
6.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026)
7.2 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
7.3 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors by Region (2021-2026)
8.2 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
8.3 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS MARKET FORECAST
10.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.1.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.1.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.4 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.1.5 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2 Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Country (2027-2032)
10.2.1 United States Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.2 Canada Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.3 Mexico Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.2.4 Brazil Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3 APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.3.1 China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Forecast
10.3.2 Japan Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.3 Korea Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.4 Southeast Asia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.5 India Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.3.6 Australia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Country (2027-2032)
10.4.1 Germany Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.2 France Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.3 UK Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.4 Italy Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.4.5 Russia Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5 Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Region (2027-2032)
10.5.1 Egypt Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.2 South Africa Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.3 Israel Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.5.4 Turkey Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
10.6 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Type (2027-2032)
10.7 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market CD73 and DDR1-Targeted Drugs for Digestive System Tumors Forecast
11 KEY PLAYERS ANALYSIS
11.1 Arcus Biosciences / Gilead Sciences
11.1.1 Arcus Biosciences / Gilead Sciences Company Information
11.1.2 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.1.3 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Arcus Biosciences / Gilead Sciences Main Business Overview
11.1.5 Arcus Biosciences / Gilead Sciences Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.2.3 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Akeso
11.3.1 Akeso Company Information
11.3.2 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.3.3 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Akeso Main Business Overview
11.3.5 Akeso Latest Developments
11.4 TJ Bio
11.4.1 TJ Bio Company Information
11.4.2 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.4.3 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 TJ Bio Main Business Overview
11.4.5 TJ Bio Latest Developments
11.5 I-Mab Biopharma
11.5.1 I-Mab Biopharma Company Information
11.5.2 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.5.3 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 I-Mab Biopharma Main Business Overview
11.5.5 I-Mab Biopharma Latest Developments
11.6 Innate Pharma
11.6.1 Innate Pharma Company Information
11.6.2 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.6.3 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Innate Pharma Main Business Overview
11.6.5 Innate Pharma Latest Developments
11.7 Phanes Therapeutics
11.7.1 Phanes Therapeutics Company Information
11.7.2 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.7.3 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Phanes Therapeutics Main Business Overview
11.7.5 Phanes Therapeutics Latest Developments
11.8 Incyte Corp
11.8.1 Incyte Corp Company Information
11.8.2 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
11.8.3 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Incyte Corp Main Business Overview
11.8.5 Incyte Corp Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of CD73 Target
Table 4. Major Players of DDR1 Target
Table 5. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Table 8. Major Players of 68Ga
Table 9. Major Players of 18F
Table 10. Major Players of Lu177
Table 11. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Nucleoside (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside (2021-2026) & ($ millions)
Table 13. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2021-2026)
Table 14. Major Players of Gastric Cancer
Table 15. Major Players of Colorectal Cancer
Table 16. Major Players of Pancreatic Cancer
Table 17. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Indications (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications (2021-2026) & ($ millions)
Table 19. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2021-2026)
Table 20. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 22. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Table 23. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026) & ($ millions)
Table 24. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player (2021-2026)
Table 25. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Key Players Head office and Products Offered
Table 26. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 30. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Table 31. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country (2021-2026)
Table 35. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Table 37. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Table 39. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Table 41. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country (2021-2026)
Table 45. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 51. Key Market Challenges & Risks of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 52. Key Industry Trends of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 53. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Arcus Biosciences / Gilead Sciences Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 58. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 59. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Arcus Biosciences / Gilead Sciences Main Business
Table 61. Arcus Biosciences / Gilead Sciences Latest Developments
Table 62. AstraZeneca Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 63. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 64. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. AstraZeneca Main Business
Table 66. AstraZeneca Latest Developments
Table 67. Akeso Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 68. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 69. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Akeso Main Business
Table 71. Akeso Latest Developments
Table 72. TJ Bio Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 73. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 74. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. TJ Bio Main Business
Table 76. TJ Bio Latest Developments
Table 77. I-Mab Biopharma Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 78. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 79. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. I-Mab Biopharma Main Business
Table 81. I-Mab Biopharma Latest Developments
Table 82. Innate Pharma Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 83. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 84. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Innate Pharma Main Business
Table 86. Innate Pharma Latest Developments
Table 87. Phanes Therapeutics Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 88. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 89. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Phanes Therapeutics Main Business
Table 91. Phanes Therapeutics Latest Developments
Table 92. Incyte Corp Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 93. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 94. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Incyte Corp Main Business
Table 96. Incyte Corp Latest Developments
Table 1. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of CD73 Target
Table 4. Major Players of DDR1 Target
Table 5. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Table 8. Major Players of 68Ga
Table 9. Major Players of 18F
Table 10. Major Players of Lu177
Table 11. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Nucleoside (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside (2021-2026) & ($ millions)
Table 13. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2021-2026)
Table 14. Major Players of Gastric Cancer
Table 15. Major Players of Colorectal Cancer
Table 16. Major Players of Pancreatic Cancer
Table 17. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Indications (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications (2021-2026) & ($ millions)
Table 19. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2021-2026)
Table 20. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 22. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Table 23. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026) & ($ millions)
Table 24. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player (2021-2026)
Table 25. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Key Players Head office and Products Offered
Table 26. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 30. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Table 31. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country (2021-2026)
Table 35. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Table 37. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Table 39. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Table 41. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country (2021-2026)
Table 45. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 51. Key Market Challenges & Risks of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 52. Key Industry Trends of CD73 and DDR1-Targeted Drugs for Digestive System Tumors
Table 53. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Arcus Biosciences / Gilead Sciences Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 58. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 59. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Arcus Biosciences / Gilead Sciences Main Business
Table 61. Arcus Biosciences / Gilead Sciences Latest Developments
Table 62. AstraZeneca Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 63. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 64. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. AstraZeneca Main Business
Table 66. AstraZeneca Latest Developments
Table 67. Akeso Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 68. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 69. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Akeso Main Business
Table 71. Akeso Latest Developments
Table 72. TJ Bio Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 73. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 74. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. TJ Bio Main Business
Table 76. TJ Bio Latest Developments
Table 77. I-Mab Biopharma Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 78. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 79. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. I-Mab Biopharma Main Business
Table 81. I-Mab Biopharma Latest Developments
Table 82. Innate Pharma Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 83. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 84. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Innate Pharma Main Business
Table 86. Innate Pharma Latest Developments
Table 87. Phanes Therapeutics Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 88. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 89. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Phanes Therapeutics Main Business
Table 91. Phanes Therapeutics Latest Developments
Table 92. Incyte Corp Details, Company Type, CD73 and DDR1-Targeted Drugs for Digestive System Tumors Area Served and Its Competitors
Table 93. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product Offered
Table 94. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Incyte Corp Main Business
Table 96. Incyte Corp Latest Developments
LIST OF FIGURES
Figure 1. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales Market Share by Country/Region (2025)
Figure 8. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type in 2025
Figure 10. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside in 2025
Figure 11. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications in 2025
Figure 12. CD73 and DDR1-Targeted Drugs for Digestive System Tumors in Diagnosis
Figure 13. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Diagnosis (2021-2026) & ($ millions)
Figure 14. CD73 and DDR1-Targeted Drugs for Digestive System Tumors in Therapeutics
Figure 15. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Therapeutics (2021-2026) & ($ millions)
Figure 16. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application in 2025
Figure 17. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player in 2025
Figure 18. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Figure 19. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 20. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 21. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 23. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Value Market Share by Country in 2025
Figure 24. United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region in 2025
Figure 29. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 30. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 31. China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 35. India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country in 2025
Figure 38. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 39. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 40. Germany CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 41. France CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 54. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 55. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 57. United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 58. Canada CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 59. Mexico CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 60. Brazil CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 61. China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 62. Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 63. Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 65. India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 66. Australia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 67. Germany CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 68. France CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 69. UK CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 70. Italy CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 71. Russia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 72. Egypt CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 73. South Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 74. Israel CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 75. Turkey CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 76. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 1. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales Market Share by Country/Region (2025)
Figure 8. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type in 2025
Figure 10. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside in 2025
Figure 11. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications in 2025
Figure 12. CD73 and DDR1-Targeted Drugs for Digestive System Tumors in Diagnosis
Figure 13. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Diagnosis (2021-2026) & ($ millions)
Figure 14. CD73 and DDR1-Targeted Drugs for Digestive System Tumors in Therapeutics
Figure 15. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Therapeutics (2021-2026) & ($ millions)
Figure 16. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application in 2025
Figure 17. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Player in 2025
Figure 18. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Figure 19. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 20. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 21. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2021-2026 ($ millions)
Figure 23. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Value Market Share by Country in 2025
Figure 24. United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region in 2025
Figure 29. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 30. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 31. China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 35. India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Country in 2025
Figure 38. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 39. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 40. Germany CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 41. France CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 54. APAC CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 55. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 57. United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 58. Canada CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 59. Mexico CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 60. Brazil CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 61. China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 62. Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 63. Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 65. India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 66. Australia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 67. Germany CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 68. France CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 69. UK CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 70. Italy CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 71. Russia CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 72. Egypt CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 73. South Africa CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 74. Israel CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 75. Turkey CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
Figure 76. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size 2027-2032 ($ millions)
